The NIH Cap on Indirect Rates for Research Institutions
This Viewpoint examines the National Institutes of Health’s 15% uniform cap on indirect cost reimbursements for all federally funded biomedical research and the litigation that followed from a coalition of 22 states.
This Viewpoint examines the National Institutes of Health’s 15% uniform cap on indirect cost reimbursements for all federally funded biomedical research and the litigation that followed from a coalition of 22 states.
